Bevacizumab and Glioblastoma: Past, Present, and Future Directions

  title={Bevacizumab and Glioblastoma: Past, Present, and Future Directions},
  author={M. Kim and Yoshie Umemura and D. Leung},
  journal={The Cancer Journal},
  • M. Kim, Yoshie Umemura, D. Leung
  • Published 2018
  • Medicine
  • The Cancer Journal
  • Abstract Glioblastoma (GBM) is the most common and lethal intracranial malignancy, with few advances in treatment over the last several decades. Much excitement surrounded the initial approval for bevacizumab for recurrent GBM, given the marked radiographic responses and improvement in progression-free survival observed in early studies. However, phase III studies have failed to demonstrate an overall survival advantage with the use of this agent. An overview of the mechanism of action and… CONTINUE READING
    14 Citations

    Topics from this paper.

    Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
    • 1
    • Highly Influenced
    • PDF
    Changes in the tumor microenvironment and treatment outcome in glioblastoma: A pilot study
    Immunohistochemical Characterization of Immune Infiltrate in Tumor Microenvironment of Glioblastoma


    Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
    • 64
    • PDF
    Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
    • 76
    • PDF
    Lomustine and Bevacizumab in Progressive Glioblastoma
    • 232
    • PDF
    Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
    • T. Sandmann, R. Bourgon, +16 authors C. Bais
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2015
    • 188
    Bevacizumab for recurrent malignant gliomas
    • 516